RHYTHM PHARMACEUTICALS, INC. Total Liabilities and Equity
RHYTHM PHARMACEUTICALS, INC. (RYTM) had Total Liabilities and Equity of $437.27 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-04
- 2026-06-30: Liabilities and Equity $437.27M.
- 2026-03-31: Liabilities and Equity $442.32M.
- 2025-12-31: Liabilities and Equity $480.20M.
- 2025-09-30: Liabilities and Equity $506.87M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $437.27M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $442.32M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $480.20M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $506.87M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $372.73M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $386.69M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $392.27M 10-K · filed 2026-02-26 |
| 2024-09-30 | $363.57M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $381.85M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $258.65M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $332.75M 10-K · filed 2025-02-28 |
| 2023-09-30 | $354.20M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $309.94M 10-Q · filed 2023-08-01 |
| 2023-03-31 | $345.68M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $382.48M 10-K · filed 2024-02-29 |
| 2022-09-30 | $389.61M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $277.68M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $284.82M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $329.52M 10-K · filed 2023-03-01 |
| 2021-09-30 | $355.82M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $388.39M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $422.21M 10-Q · filed 2021-05-03 |
| 2020-12-31 | $187.07M 10-K · filed 2022-03-01 |
| 2020-09-30 | $215.48M 10-Q · filed 2020-11-02 |
| 2020-06-30 | $243.49M 10-Q · filed 2020-08-03 |
| 2020-03-31 | $273.76M 10-Q · filed 2020-05-04 |
| 2019-12-31 | $308.52M 10-K · filed 2021-03-01 |
| 2019-09-30 | $177.53M 10-Q · filed 2019-11-01 |
| 2019-06-30 | $210.89M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $236.50M 10-Q · filed 2019-05-03 |
| 2018-12-31 | $260.21M 10-K · filed 2020-03-02 |
| 2018-09-30 | $277.73M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $291.75M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $139.44M 10-Q · filed 2018-05-14 |
| 2017-12-31 | $151.74M 10-K · filed 2019-03-08 |
| 2017-09-30 | $34.80M 10-Q · filed 2017-11-14 |
| 2016-12-31 | $12.34M 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |